Viking Therapeutics : July 2025 Corporate Presentation

Published: 2025-07-02 19:47:04 ET VKTX

Published on 07/02/2025 at 19:47

Corporate Presentation

July 2025

Investment Highlights

Developing novel therapeutics for metabolic and endocrine diseases

Multiple clinical programs demonstrate best-in-class efficacy data

Metabolic Disease Programs

VK2735: GLP-1/GIP dual agonist for obesity

VENTURE Phase 2 obesity study successfully achieved primary endpoint; Phase 3 underway

VK2735 Oral: GLP-1/GIP dual agonist for obesity

Phase 1 study demonstrated positive PoC, reduction in body weight; Phase 2 underway

Amylin agonist for obesity

IND planned 4Q25

Additional Programs

VK2809: Selective thyroid receptor-β agonist for MASH; successful Phase 2b reported 2Q24

VK0214: Selective thyroid receptor-β agonist for X-ALD; successful Phase 1b reported 4Q24

Pipeline Overview

Development Programs

Indication

Stage of Development

Status

Preclin

Phase 1

Phase 2

Phase 3

VK2735 Subcutaneous (Dual GLP-1/GIP agonist)

Obesity

Phase 3 underway; Phase 1 monthly study planned 3Q25

VK2735 Oral

(Dual GLP-1/GIP agonist)

Obesity

Phase 2 underway

Amylin agonist

Obesity

IND planned 4Q25

Additional metabolic

VK2809

(TRβ agonist)

MASH

Phase 2b VOYAGE trial successfully completed

VK0214

(TRβ agonist)

X-ALD

Phase 1b study demonstrated PoC

VK2735: Dual GLP-1/GIP Receptor Agonist

Metabolic Disorders

Disclaimer

Viking Therapeutics Inc. published this content on July 02, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 02, 2025 at 23:46 UTC.